KRAS and pancreatic ductal adenocarcinoma: Some inadvertent mistake in our paper entitled “The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super‐enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis‐generating study” [1] and published in Clinical and translational medicine came to our attention recently: